High demand leaves Ozempic compensating for Wegovy’s supply shortage: GlobalData

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival

Briefs: Piramal Enterprises and Shilpa Medicare

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval

Orchid Pharma launches Rs. 500 Cr QIP programme

With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023

WuXi STA launches parenteral formulation manufacturing line at Wuxi

This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

Gland Pharma to buy French pharma company Cenexi

Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group

Japan approves ENHERTU for treatment of adult patients with HER2 positive unresectable breast cancer

Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial

Chantal van Gils joins NDA Advisory Board as Director of Epidemiology

She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy